Dicerna Pharmaceuticals
Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.
General Information
Get notified when Dicerna Pharmaceuticals moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Dicerna Pharmaceuticals
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Biotechnology
About Dicerna Pharmaceuticals
Taxonomy: RNA Interference, Genetic Disorders, Liver Diseases, Rare Diseases, Therapeutics, RNAi Technology, Pharmaceuticals, Drug Discovery, Inherited Liver Diseases, Cancer Treatment, Cardiovascular Disease, Hepatitis B, Orphan Genetic Diseases, Medical Research
Funding Rounds & Investors (8)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | •••••• | 2 |
|
29 Oct 2018 |
| Post-IPO Equity | •••••• | - | 16 May 2018 | |
| Post-IPO Debt | •••••• | 6 |
|
30 Mar 2017 |
| Post-IPO Equity | •••••• | - | 20 May 2015 | |
| Series C | •••••• | 9 |
|
31 Jul 2013 |
Dicerna Pharmaceuticals Alternatives & Competitors
Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.
Empowering health with advanced solutions against liver disease and comprehensive molecular testing...
Madrigal is focused on delivering novel therapeutics for MASH, a serious liver disease.
FAQ About Dicerna Pharmaceuticals
Don't just browse. Track.
Signal Tracker monitors Dicerna Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.